Skip to main content
Premium Trial:

Request an Annual Quote

Cenix, IMM Develop RNAi Screen for Malaria; Seek Funding for Larger Assay

NEW YORK, June 29 (GenomeWeb News) - Researchers at the Instituto de Medicina Molecular in Lisbon, Portugal, and Cenix Bioscience hjave developed an RNAi screen for malaria genes that may lead to better anti-malarial therapeutics, the IMM and Cenix said in a statement.

 

The screen is based on an in vitro assay developed by Maria Mota's lab at the IMM that monitors the response of human liver cells to malaria infection. Dresden, Germany-based Cenix adapted Mota's assay for high-throughput RNAi screening, and a pilot study using the screen has been completed.

 

According to the two partners, a larger screen is now underway that "will cover over 800 human genes including all known kinases, key regulators of nearly all cellular pathways." They are also seeking additional funding to expand the capabilities of the assay, they said.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.